Login to Your Account



Other News To Note


Wednesday, December 28, 2011
• Gilead Sciences Inc., of Foster City, Calif., said the FDA accepted for review its new drug application for the Quad single-tablet HIV regimen containing elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. The agency, however, denied the firm's request for priority review. A standard 10-month review sets the PDUFA date at Aug. 27, 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription